Skip to content
Research Article Open access CC BY 4.0

Progress in the Treatment of Henoch-Schonlein Purpura in Children

Zhaoyu Yang, Jiemin Wang, Fuyong Jiao

International Journal of TROPICAL DISEASE & Health · pp. 14–20 · Published 27 Aug 2022

10.9734/ijtdh/2022/v43i1730657

Abstract

Henoch-Schonlein Purpura (HSP) is the most common leukocyte fragmentary vasculitis with IgA immune complex deposition in childhood, which may affect capillaries, arterioles and venules in various systems of the body. Henoch-Schonlein purpura nephritis (HSPN) can be diagnosed when kidney damage occurs in children with HSP, which is the most severe complication of HSP. However, if the treatment of children with HSPN is delayed or recurrent, more than 20% of these children eventually develop chronic renal failure, seriously affecting the prognosis and quality of life of the children. Therefore, early diagnosis and treatment are crucial to the prognosis of children with HSP. This article reviews the treatment of HSP and HSPN.

Henoch-Schonlein purpura nephritis treatment

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

1

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.